A potent mix of local politics and public pressure has intruded on the smoothness of the executive succession at Swiss multinational Novartis AG, with its outgoing chairman and controversial figure in Switzerland Daniel Vasella cancelling a CHF 72 million ($78 million) non-compete compensation deal following a public outcry.
The proposed deal added fuel to the already inflamed debate in Switzerland on what is or isn’t excessive executive pay....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?